Amicus Therapeutics Inc. (NASDAQ:FOLD)‘s stock had its “overweight” rating reaffirmed by JPMorgan Chase & Co. in a research report issued to clients and investors on Wednesday. They currently have a $11.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $12.00. JPMorgan Chase & Co.’s price target points to a potential upside of 68.97% from the company’s current price.

FOLD has been the subject of several other research reports. Chardan Capital restated a “buy” rating on shares of Amicus Therapeutics in a research note on Tuesday. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 18th. Cowen and Company restated an “outperform” rating and issued a $15.00 price objective on shares of Amicus Therapeutics in a research note on Tuesday, November 8th. Robert W. Baird restated a “hold” rating and issued a $7.00 price objective (down previously from $9.00) on shares of Amicus Therapeutics in a research note on Tuesday. Finally, Leerink Swann restated a “buy” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a research note on Tuesday, November 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $11.53.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) opened at 6.51 on Wednesday. The company has a 50 day moving average price of $7.82 and a 200 day moving average price of $6.97. The stock’s market cap is $926.54 million. Amicus Therapeutics has a 52 week low of $4.98 and a 52 week high of $11.02.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The company earned $2.10 million during the quarter, compared to analyst estimates of $1.71 million. Analysts expect that Amicus Therapeutics will post ($1.38) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Amicus Therapeutics’ (FOLD) “Overweight” Rating Reaffirmed at JPMorgan Chase & Co.” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was stolen and republished in violation of US & international trademark and copyright laws. The original version of this news story can be accessed at http://www.dailypolitical.com/2016/11/29/amicus-therapeutics-fold-overweight-rating-reaffirmed-at-jpmorgan-chase-co.html.

In related news, SVP Daphne Quimi sold 8,546 shares of the stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $8.00, for a total transaction of $68,368.00. Following the completion of the transaction, the senior vice president now directly owns 24,189 shares of the company’s stock, valued at $193,512. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Hung Do sold 25,000 shares of the stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $7.00, for a total transaction of $175,000.00. Following the transaction, the insider now directly owns 583,453 shares of the company’s stock, valued at $4,084,171. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of FOLD. FMR LLC boosted its position in Amicus Therapeutics by 1.6% in the second quarter. FMR LLC now owns 19,023,053 shares of the biopharmaceutical company’s stock valued at $103,865,000 after buying an additional 299,950 shares in the last quarter. Redmile Group LLC boosted its position in Amicus Therapeutics by 14.8% in the third quarter. Redmile Group LLC now owns 12,751,536 shares of the biopharmaceutical company’s stock valued at $94,361,000 after buying an additional 1,645,090 shares in the last quarter. Jennison Associates LLC boosted its position in Amicus Therapeutics by 53.6% in the third quarter. Jennison Associates LLC now owns 7,906,476 shares of the biopharmaceutical company’s stock valued at $58,508,000 after buying an additional 2,759,262 shares in the last quarter. Vanguard Group Inc. boosted its position in Amicus Therapeutics by 8.1% in the second quarter. Vanguard Group Inc. now owns 7,033,500 shares of the biopharmaceutical company’s stock valued at $38,404,000 after buying an additional 524,050 shares in the last quarter. Finally, BlackRock Fund Advisors boosted its position in shares of Amicus Therapeutics by 14.7% in the third quarter. BlackRock Fund Advisors now owns 6,634,693 shares of the biopharmaceutical company’s stock worth $49,097,000 after buying an additional 849,379 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.